Patient profiling in diabetes and role of canagliflozin

References

• AliMKMcKeever BullardKImperatoreGBarkerLGreggEWCenters for Disease Control and Prevention (CDC)Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes – National Health and Nutrition Examination Survey, United States, 2007–2010MMWR Morb Mortal Wkly RepSuppl61323722695461
   PubMedGoogle Scholar
• InzucchiSEBergenstalRMBuseJBAmerican Diabetes Association (ADA)European Association for the Study of Diabetes (EASD)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• InzucchiSEOral antihyperglycemic therapy for type 2 diabetes: scientific reviewJAMA2002287336037211790216
   PubMed Web of Science ®Google Scholar
• DonnellyLADoneyASHattersleyATMorrisADPearsonERThe effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetesDiabet Med200623212813316433709
   PubMed Web of Science ®Google Scholar
• GrahamGGPuntJAroraMClinical pharmacokinetics of metforminClin Pharmacokinet2011502819821241070
   PubMed Web of Science ®Google Scholar
• OtsukaMMatsumotoTMorimotoRAriokaSOmoteHMoriyamaYA human transporter protein that mediates the final excretion step for toxic organic cationsProc Natl Acad Sci U S A200510250179231792816330770
   PubMed Web of Science ®Google Scholar
• BeckerMLVisserLEvan SchaikRHHofmanAUitterlindenAGStrickerBHGenetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitusPharmacogenomics J20099424224719381165
   PubMed Web of Science ®Google Scholar
• TaniharaYMasudaSSatoTKatsuraTOgawaOInuiKSubstrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiportersBiochem Pharmacol200774235937117509534
   PubMed Web of Science ®Google Scholar
• ShikataEYamamotoRTakaneHHuman organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metforminJ Hum Genet200752211712217111267
   PubMed Web of Science ®Google Scholar
• ZhouKBellenguezCSpencerCCGoDARTS and UKPDS Diabetes Pharmacogenetics Study GroupWellcome Trust Case Control Consortium 2MAGIC investigatorsCommon variants near ATM are associated with glycemic response to metformin in type 2 diabetesNat Genet201143211712021186350
   PubMed Web of Science ®Google Scholar
• ChristensenMMBrasch-AndersenCGreenHThe pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1cPharmacogenet Genomics2011211283785021989078
   PubMed Web of Science ®Google Scholar
• LavrenkoAVShlykovaOAKutsenkoLAMamontovaTVKaĭdashevIPPharmacogenetic features of the effect of metformin in patients with coronary heart disease in the presence of metabolic syndrome and type 2 diabetes mellitus in terms of PPAR-gamma2 gene polymorphismTer Arkh20128493540 Russian23091851
   PubMed Web of Science ®Google Scholar
• PearsonERLiddellWGShepherdMCorrallRJHattersleyATSensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetesDiabet Med200017754354510972586
   PubMed Web of Science ®Google Scholar
• JavorskyMKlimcakovaLSchronerZKCNJ11 gene E23K variant and therapeutic response to sulfonylureasEur J Intern Med201223324524922385882
   PubMed Web of Science ®Google Scholar
• SestiGLarattaECardelliniMThe E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetesJ Clin Endocrinol Metab20069162334233916595597
   PubMed Web of Science ®Google Scholar
• SestiGMariniMACardelliniMThe Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetesDiabetes Care20042761394139815161794
   PubMed Web of Science ®Google Scholar
• LangVYFatehiMLightPEPharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369APharmacogenet Genomics201222320621422209866
   PubMed Web of Science ®Google Scholar
• SchronerZDobrikovaMKlimcakovaLVariation in KCNQ1 is associated with therapeutic response to sulphonylureasMed Sci Monit2011177CR392CR39621709633
   PubMed Web of Science ®Google Scholar
• DaiXPHuangQYinJYKCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patientsClin Exp Pharmacol Physiol201239546246822414228
   PubMed Web of Science ®Google Scholar
• YuWHuCZhangREffects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetesClin Pharmacol Ther201189343744221289621
   PubMed Web of Science ®Google Scholar
• GongZCHuangQDaiXPNeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetesBr J Clin Pharmacol201274350150922296034
   PubMed Web of Science ®Google Scholar
• HuangQYinJYDaiXPAssociation analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patientsEur J Clin Pharmacol201066121207121520809084
   PubMed Web of Science ®Google Scholar
• KangESParkSYKimHJEffects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetesClin Pharmacol Ther200578220220816084854
   PubMed Web of Science ®Google Scholar
• HsiehMCLinKDTienKJCommon polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitusMetabolism20105981139114420045142
   PubMed Web of Science ®Google Scholar
• BlüherMLübbenGPaschkeRAnalysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetesDiabetes Care200326382583112610044
   PubMed Web of Science ®Google Scholar
• NamvaranFAzarpiraNRahimi-MoghaddamPDabbaghmaneshMHPolymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetesEur J Pharmacol20116711–31621968139
   PubMed Web of Science ®Google Scholar
• Kawaguchi-SuzukiMFryeRFCurrent clinical evidence on pioglitazone pharmacogenomicsFront Pharmacol2013414724324437
   PubMed Web of Science ®Google Scholar
• PeiQHuangQYangGPPPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients’ response to pioglitazone in ChinaActa Pharmacol Sin201334225526123147557
   PubMed Web of Science ®Google Scholar
• ZhangKHHuangQDaiXPEffects of the peroxisome proliferator activated receptor-γ coactivator-1α (PGC-1α) Thr394Thr and Gly482Ser polymorphisms on rosiglitazone response in Chinese patients with type 2 diabetes mellitusJ Clin Pharmacol20105091022103020498286
   PubMed Web of Science ®Google Scholar
• LiuHLLinYGWuJImpact of genetic polymorphisms of leptin and TNF-alpha on rosiglitazone response in Chinese patients with type 2 diabetesEur J Clin Pharmacol200864766367118438653
   PubMed Web of Science ®Google Scholar
• MakinoHShimizuIMuraoSA pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at −420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetesEndocr J20095691049105819738363
   PubMed Web of Science ®Google Scholar
• SunHGongZCYinJYThe association of adiponectin allele 45T/G and −11377C/G polymorphisms with Type 2 diabetes and rosiglitazone response in Chinese patientsBr J Clin Pharmacol200865691792618429970
   PubMed Web of Science ®Google Scholar
• LiZPengXWuYXiaYLiuXZhangQThe influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetesDiabetes Obes Metab200810979480218494805
   PubMed Web of Science ®Google Scholar
• NamvaranFRahimi-MoghaddamPAzarpiraNDabbaghmaneshMHPolymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitusMol Biol Rep20123955511551822187345
   PubMed Web of Science ®Google Scholar
• YangMHuangQWuJEffects of UCP2 -866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetesBr J Clin Pharmacol2009681142219659999
   PubMed Web of Science ®Google Scholar
• WangGWangXZhangQMaZResponse to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitusInt J Clin Pract200761455255717394430
   PubMed Web of Science ®Google Scholar
• SathananthanAManCDMichelettoFCommon genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot studyDiabetes Care20103392074207620805279
   PubMed Web of Science ®Google Scholar
• MüssigKStaigerHMachicaoFAssociation of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretionDiabetes20095871715172019366866
   PubMed Web of Science ®Google Scholar
• ShuLMatveyenkoAVKerr-ConteJChoJHMcIntoshCHMaedlerKDecreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell functionHum Mol Genet200918132388239919386626
   PubMed Web of Science ®Google Scholar
• SchäferSATschritterOMachicaoFImpaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphismsDiabetologia200750122443245017661009
   PubMed Web of Science ®Google Scholar
• VillarealDTRobertsonHBellGITCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin actionDiabetes201059247948519934000
   PubMed Web of Science ®Google Scholar
• SchäferSAMüssigKStaigerHA common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretionDiabetologia20095261075108219330314
   PubMed Web of Science ®Google Scholar
• Simonis-BikAMNijpelsGvan HaeftenTWGene variants in the novel type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic beta-cell functionDiabetes201059129330119833888
   PubMed Web of Science ®Google Scholar
• AquilanteCLWempeMFSidhomMSKosmiskiLAPredhommeJAEffect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteersEur J Clin Pharmacol20136971401140923407853
   PubMed Web of Science ®Google Scholar
• KwonOChoeEYChoiYDiscovery of dipeptidyl peptidase-4 gene variants and the associations with efficacy of vildagliptin in patients with type 2 diabetes – a pilot studyJ Diabetes Metab2013S13006
   Google Scholar
• WellsRGMohandasTKHedigerMALocalization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromereGenomics19931737877898244402
   PubMed Web of Science ®Google Scholar
• YuLLvJCZhouXJZhuLHouPZhangHAbnormal expression and dysfunction of novel SGLT2 mutations identified in familial renal glucosuria patientsHum Genet2011129333534421165652
   PubMed Web of Science ®Google Scholar
• LeeYWClinical and genetic analysis in a patient with primary renal glucosuria: Identification of a novel mutation in the SLC5A2 geneExp Ther Med2013661532153424255686
   PubMed Web of Science ®Google Scholar
• EnigkUBreitfeldJSchleinitzDRole of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasisPharmacogenomics20111281119112621830867
   PubMed Web of Science ®Google Scholar
• StenlöfKCefaluWTKimKAEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes Obes Metab201315437238223279307
   PubMed Web of Science ®Google Scholar
• WildingJPMathieuCVercruysseFUsiskinKDengLCanovatchelWCanagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes (T2D) inadequately controlled with metformin (MET) and sulfonylurea (SU)Poster presented at: American Diabetes Association 72nd Annual Scientific SessionsJune 8–12, 2012Philadelphia, PA Abstract 1022P
   Google Scholar
• ForstTGuthrieRGoldenbergREfficacy and safety of canagliflozin in subjects with type 2 diabetes on metformin and pioglitazonePoster presented at: 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)November 8–11, 2012Barcelona, Spain Board 64
   Google Scholar
• CefaluWTLeiterLAYoonKHEfficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialLancet2013382989694195023850055
   PubMed Web of Science ®Google Scholar
• GrossJLSchernthanerGFuMEfficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with sitagliptin in patients with type 2 diabetes on metformin plus sulfonylureaAbstract presented at: American Diabetes Association 72nd Annual Scientific SessionsJune 8–12, 2012Philadelphia, PA Abstract 50
   Google Scholar
• Lavalle-GonzálezFJJanuszewiczADavidsonJEfficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia201356122582259224026211
   PubMed Web of Science ®Google Scholar
• ToubroSCefaluWTXieJCanagliflozin reduces body weight mainly through loss of fat mass in subjects with type 2 diabetesPoster presented at: 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)November 8–11, 2012Barcelona, Spain Board 72
   Google Scholar
• SinclairABodeBHarrisSEfficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesBMC Endocr Disord2014143724742013
   PubMed Web of Science ®Google Scholar
• ElmoreLKBaggettSKyleJASkelleyJWA review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetesConsult Pharm201429533534624849690
   PubMedGoogle Scholar
• PolidoriDMariAFerranniniECanagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetesDiabetologia201457589190124585202
   PubMed Web of Science ®Google Scholar
• DevineniDVaccaroNPolidoriDRuschSWajsEEffects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participantsClin Ther201436569871024726680
   PubMed Web of Science ®Google Scholar
• ShaSPolidoriDHeiseTEffect of the sodium glucose co-transporter 2 inhibitor, canagliflozin, on plasma volume in patients with type 2 diabetes mellitusDiabetes Obes Metab2014161087109524939043
   PubMed Web of Science ®Google Scholar
• NyirjesyPSobelJDFungAGenital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studiesCurr Med Res Opin20143061109111924517339
   PubMed Web of Science ®Google Scholar
• AquilanteCLWempeMFSpencerSHKosmiskiLAPredhommeJASidhomMSInfluence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteersPharmacotherapy20133391000100723712614
   PubMed Web of Science ®Google Scholar
• MartisSPeterIHulotJSKornreichRDesnickRJScottSAMulti-ethnic distribution of clinically relevant CYP2C genotypes and haplotypesPharmacogenomics J201313436937722491019
   PubMed Web of Science ®Google Scholar
• GrantRWHivertMPandiscioJCFlorezJCNathanDMMeigsJBThe clinical application of genetic testing in type 2 diabetes: a patient and physician surveyDiabetologia200952112299230519727660
   PubMed Web of Science ®Google Scholar